LUIS
BUJANDA FERNÁNDEZ DE PIÉROLA
Hospital Miguel Servet
Zaragoza, EspañaHospital Miguel Servet -ko ikertzaileekin lankidetzan egindako argitalpenak (34)
2024
-
Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study)
Alimentary Pharmacology and Therapeutics, Vol. 59, Núm. 10, pp. 1248-1259
-
Gene content, phage cycle regulation model and prophage inactivation disclosed by prophage genomics in the Helicobacter pylori Genome Project
Gut Microbes, Vol. 16, Núm. 1
-
Initial Management of Intra-abdominal Abscesses and Preventive Strategies for Abscess Recurrence in Penetrating Crohn's Disease: A National, Multicentre Study Based on ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 4, pp. 578-588
-
Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula in Crohn's disease: The HEAL study from GETECCU
Digestive and Liver Disease, Vol. 56, Núm. 11, pp. 1845-1853
-
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290
-
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
Pharmaceutics, Vol. 16, Núm. 5
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
-
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study
Alimentary Pharmacology and Therapeutics, Vol. 58, Núm. 1, pp. 60-70
-
Splanchnic Vein Thrombosis in Inflammatory Bowel Disease: An Observational Study from the ENEIDA Registry and Systematic Review
Journal of Clinical Medicine, Vol. 12, Núm. 23
-
The Helicobacter pylori Genome Project: insights into H. pylori population structure from analysis of a worldwide collection of complete genomes
Nature Communications, Vol. 14, Núm. 1
2022
-
Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study
Journal of Clinical Medicine, Vol. 11, Núm. 17
-
Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts
Frontiers in Medicine, Vol. 9
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU
Journal of Clinical Medicine, Vol. 11, Núm. 13
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
V Spanish Consensus Conference on Helicobacter pylori infection treatment
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 392-417
2021
-
Clinical practice guidelines. v spanish consensus conference on helicobacter pylori infection treatment
Revista Espanola de Enfermedades Digestivas, Vol. 113, Núm. 10, pp. 740-763
-
Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry
Digestive Diseases and Sciences, Vol. 66, Núm. 6, pp. 2014-2023
2020
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616